Oct 29, 7:05 AM ET
Bristol Myers Squibb reported third-quarter 2026 total revenues of $13.1 billion, representing a 7% increase compared to the same period in 2025. The company raised its full-year 2026 revenue guidance range to $49.75 billion to $50.25 billion, driven by momentum in its Growth Portfolio.
- Third-quarter total revenues increased 7% to $13.1 billion compared to $12.2 billion in 2025.
- GAAP EPS was $1.05 and non-GAAP EPS was $1.35 for the third quarter of 2026.
- Full-year 2026 revenue guidance was raised to a range of $49.75 billion to $50.25 billion.
- Non-GAAP EPS guidance for 2026 was updated to a range of $6.35 to $6.55.
Read the filing on SEC.gov ↗
Jul 30, 7:05 AM ET
Bristol Myers Squibb reported second-quarter 2026 revenue of $13.0 billion, up 6% from a year earlier, and GAAP earnings of $1.62 per share, up from $0.64. The company raised its full-year 2026 revenue guidance to approximately $49.0 billion to $50.0 billion from $46.0 billion to $47.5 billion, and its non-GAAP EPS range to $6.75 to $7.00 from $6.05 to $6.35, which matters to shareholders because it signals higher expected profit for the year.
- Q2 revenue was $12,973 million, up 6% (5% excluding foreign exchange); Growth Portfolio revenue rose 15% to $7.6 billion while Legacy Portfolio revenue fell 4% to $5.4 billion.
- GAAP EPS was $1.62 versus $0.64 a year earlier; non-GAAP EPS was $2.04 versus $1.46.
- 2026 non-GAAP revenue guidance was raised to approximately $49.0 billion to $50.0 billion; non-GAAP EPS guidance was raised to $6.75 to $7.00.
- Worldwide Eliquis revenue growth guidance for 2026 was raised to 20% to 25%, from 10% to 15%.
Read the filing on SEC.gov ↗
Apr 30, 7:01 AM ET
Bristol Myers Squibb reported first-quarter 2026 revenue of $11.5 billion, up 3% (1% excluding foreign exchange), while non-GAAP earnings per share fell 12% to $1.58 from $1.80. GAAP EPS rose 9% to $1.31, and the company reaffirmed its 2026 guidance, including non-GAAP EPS of $6.05 to $6.35, with results trending toward the upper end of the ranges.
- Growth Portfolio revenue rose 12% (9% ex-FX) to $6.2 billion, while Legacy Portfolio revenue fell 6% to $5.3 billion.
- Non-GAAP net income attributable to BMS was $3.2 billion ($1.58 per share), down from $3.7 billion ($1.80 per share) a year earlier.
- GAAP R&D expenses rose 17% to $2.6 billion, primarily due to IPRD impairment charges, and GAAP gross margin fell to 70.2% from 72.9%.
- 2026 guidance was reaffirmed with no changes from February: total revenues of about $46.0 billion to $47.5 billion and non-GAAP diluted EPS of $6.05 to $6.35.
Read the filing on SEC.gov ↗
Feb 5, 7:07 AM ET
Bristol Myers Squibb reported fourth-quarter 2025 revenue of $12.5 billion, up 1%, and non-GAAP earnings of $1.26 per share, down from $1.67 a year earlier. For full-year 2025, revenue was $48.2 billion, roughly flat, and non-GAAP EPS was $6.15, up from $1.15. The company guided 2026 revenue to $46.0 billion to $47.5 billion and non-GAAP EPS to $6.05 to $6.35.
- Q4 revenue $12.5 billion, up 1%; Growth Portfolio $7.4 billion, up 16%; Legacy Portfolio $5.1 billion, down 15%
- Q4 GAAP EPS $0.53 versus $0.04; non-GAAP EPS $1.26 versus $1.67, both including a $(0.60) net impact from Acquired IPRD charges and licensing income
- Full-year 2025 revenue $48.2 billion versus $48.3 billion; GAAP EPS $3.46 versus $(4.41)
- 2026 guidance: revenue $46.0 billion to $47.5 billion, non-GAAP EPS $6.05 to $6.35; quarterly dividend $0.63 per share, a 17th consecutive annual increase
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
